KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Debt to Equity (2016 - 2025)

Teva Pharmaceutical Industries' Debt to Equity history spans 17 years, with the latest figure at $2.12 for Q4 2025.

  • For the quarter ending Q4 2025, Debt to Equity fell 35.72% year-over-year to $2.12, compared with a TTM value of $2.12 through Dec 2025, down 35.72%, and an annual FY2025 reading of $2.12, down 35.72% over the prior year.
  • Debt to Equity for Q4 2025 was $2.12 at Teva Pharmaceutical Industries, down from $2.32 in the prior quarter.
  • The five-year high for Debt to Equity was $3.31 in Q4 2024, with the low at $2.05 in Q4 2021.
  • Average Debt to Equity over 5 years is $2.47, with a median of $2.44 recorded in 2023.
  • Year-over-year, Debt to Equity soared 35.43% in 2024 and then plummeted 35.72% in 2025.
  • Tracing TEVA's Debt to Equity over 5 years: stood at $2.05 in 2021, then increased by 20.38% to $2.47 in 2022, then fell by 1.07% to $2.44 in 2023, then soared by 35.43% to $3.31 in 2024, then plummeted by 35.72% to $2.12 in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Debt to Equity are $2.12 (Q4 2025), $2.32 (Q3 2025), and $2.52 (Q2 2025).